Main Display Panel Commercial Carton 40 mg (Image 01)
Stivarga Tablet, Film Coated
Product Images NDC 50419-171
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Stivarga (NDC 50419-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Description: Chemical Structure (Image 02)
Stivarga Gist Uspi Figure 1 V3 (Image 03)
This appears to be a graph or data table that shows the survival probability for patients who received Stivarga versus placebo over time. The x-axis represents months from randomization and the y-axis represents survival probability as a percentage. There are two lines on the graph, one for Stivarga and one for placebo, and they intersect at around 8 months. The data is broken down by the number of patients at risk for each treatment group at each time point.*
Stivarga Gist Uspi Figure 2 V3 (Image 04)
This table shows the probability of progression-free survival for patients receiving Stivarga compared to those receiving a placebo. The percentage of progression-free survival is 100%, and the number of patients at risk is shown for each group (Stivarga and Placebo). The table also includes the number of patients in each group (133 for Stivarga and 66 for Placebo).*
Fig 3 Curve Of Overall Survival (Image 05)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
